The Servier FAST Discovery Award celebrates Californian life-sciences startups and helps foster innovative approaches to advancing therapies for patients with high unmet needs. This is the third year Servier has supported this program. Servier sponsored Cenos Therapeutics for its commitment to the future of neurological health through RNA therapeutics.
The California Life Sciences Association (CLSA) FAST Program provides select entrepreneurs with intensive team review and coaching to perfect their business model and more. Our Award highlights the aspiring life-sciences companies pushing the boundaries of scientific innovation, especially in the area of hard-to-treat diseases in oncology and neuroscience as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.
This year, we recognized Cenos Therapeutics for their innovative approach to neurological health through RNA therapeutics. Their proprietary BBB-crossing conjugate RNA platform enables deep brain delivery via subcutaneous dosing, offering a potentially safer and more convenient alternative to invasive intrathecal methods. Cenos Therapeutics focuses on high-value orphan diseases like Creutzfeldt-Jakob (CJD) and Tauopathies while partnering with other companies to potentially address larger indications such as Alzheimer’s and Parkinson’s disease. Early data demonstrates significant mRNA and protein knockdown in preclinical models, with the lead program showing promise for CJD.
–
“Being part of the FAST Advisory Program with Servier was a valuable experience for Cenos. The insights and feedback we received helped us refine our business strategy and approach to fundraising as we continue advancing our platform. We appreciate Servier’s support and the opportunity to engage with industry experts who provided guidance on positioning Cenos for long-term success.”
June Park, PhD – CEO, Cenos Therapeutics
–
“As a company committed to therapeutic progress, we are proud to support the leaders of tomorrow in scientific innovation who share our commitment to addressing patients’ needs – particularly in areas with high unmet medical needs. We believe that our open and collaborative approach to supporting early-stage companies through the CLSA FAST Award is key to our long-term vision. This year we were pleased to select Cenos Therapeutics for their pioneering work in RNA therapeutics, which holds great promise in treating complex neurological diseases. Their innovative approach aligns with our dedication to advancing cutting-edge science to meet patients’ needs”
Irene Blat, Senior Director, Search & Evaluation, Oncology, Servier